ArticleBMJ open2020

A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia.

Lucy Vivash et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.